Literature DB >> 18510876

Clostridium difficile infection: a critical overview.

Bayan Missaghi1, August J Valenti, Robert C Owens.   

Abstract

Clostridium difficile is a gram-positive, spore-forming, toxin-producing anaerobic bacillus identified as the causal agent of a variety of manifestations typically isolated to the colon, but in its severe form, it can lead to sepsis and death. C. difficile infection due to a toxin gene variant strain (BI/NAP1) has been identified at the center of outbreaks and has resulted in increased mortality. Many questions remain as to how this strain appeared so quickly and has harmed or killed so many patients. We present a review of C. difficile infection, discussing its clinical presentation, diagnosis, management, and prevention.

Entities:  

Year:  2008        PMID: 18510876     DOI: 10.1007/s11908-008-0028-5

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  53 in total

1.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.

Authors:  C J Donskey; T K Chowdhry; M T Hecker; C K Hoyen; J A Hanrahan; A M Hujer; R A Hutton-Thomas; C C Whalen; R A Bonomo; L B Rice
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

Review 2.  Emerging therapies in the treatment of Clostridium difficile-associated disease.

Authors:  Tomasz Z Jodlowski; Richard Oehler; Linda W Kam; Igor Melnychuk
Journal:  Ann Pharmacother       Date:  2006-11-21       Impact factor: 3.154

3.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

4.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

5.  Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Authors:  Thomas J Louie; Jennifer Peppe; C Kevin Watt; David Johnson; Rasheed Mohammed; Gordon Dow; Karl Weiss; Stuart Simon; Joseph F John; Gary Garber; Scott Chasan-Taber; David M Davidson
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

6.  A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes.

Authors:  M Catherine McEllistrem; Robert J Carman; Dale N Gerding; C W Genheimer; L Zheng
Journal:  Clin Infect Dis       Date:  2004-12-15       Impact factor: 9.079

7.  Colonic disease associated with a positive assay for Clostridium difficile toxin: a retrospective study.

Authors:  S V Nash; R Bourgeault; M Sands
Journal:  J Clin Gastroenterol       Date:  1997-09       Impact factor: 3.062

8.  A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.

Authors:  Sophia V Kazakova; Kim Ware; Brittany Baughman; Oleg Bilukha; Anne Paradis; Stephen Sears; Angie Thompson; Bette Jensen; Lois Wiggs; Jemelie Bessette; James Martin; Judy Clukey; Kathleen Gensheimer; George Killgore; L Clifford McDonald
Journal:  Arch Intern Med       Date:  2006 Dec 11-25

Review 9.  Uses of inorganic hypochlorite (bleach) in health-care facilities.

Authors:  W A Rutala; D J Weber
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

10.  In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.

Authors:  David W Hecht; Minerva A Galang; Susan P Sambol; James R Osmolski; Stuart Johnson; Dale N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

View more
  5 in total

1.  Clostridium difficile Outbreak: A Small Group of Pharmacists Makes a Big Impact.

Authors:  Donna Bower; Frances Hachborn; Patricia Huffam
Journal:  Can J Hosp Pharm       Date:  2009-03

2.  Clostridium difficile-associated disease in children with solid tumors.

Authors:  Elio Castagnola; Teresa Battaglia; Roberto Bandettini; Ilaria Caviglia; Ivana Baldelli; Marilina Nantron; Cristina Moroni; Alberto Garaventa
Journal:  Support Care Cancer       Date:  2008-09-19       Impact factor: 3.603

3.  The potential economic value of screening hospital admissions for Clostridium difficile.

Authors:  S M Bartsch; S R Curry; L H Harrison; B Y Lee
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-30       Impact factor: 3.267

Review 4.  Probiotics in Children: What Is the Evidence?

Authors:  Iva Hojsak
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2017-09-26

5.  Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).

Authors:  E Bouza; J M Aguado; L Alcalá; B Almirante; P Alonso-Fernández; M Borges; J Cobo; J Guardiola; J P Horcajada; E Maseda; J Mensa; N Merchante; P Muñoz; J L Pérez Sáenz; M Pujol; E Reigadas; M Salavert; J Barberán
Journal:  Rev Esp Quimioter       Date:  2020-02-20       Impact factor: 1.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.